ClinicalTrials.gg
CompletedNCT07247266Updated Oct 9, 2026

Study to Evaluate the Safety, Tolerability, Efficacy and Pharmacokinetics of JTE-162 in Subjects With Cryopyrin-Associated Periodic Syndrome (CAPS)

A Phase 1 interventional study of JTE-162 in Cryopyrin-associated Periodic Syndromes (CAPS), sponsored by Akros Pharma Inc.. Completed at 1 site in Canada. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-10-09.

Sponsored by Akros Pharma Inc. (part of Shionogi) · Phase 1, Interventional, and Treatment

Updated Oct 9, 2026Primary completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
5
Allocation
Not applicable
Ages
18 Years to 80 Years
Sex
All
01

Study summary

This study will evaluate the efficacy, safety, tolerability and pharmacokinetics of JTE-162 administered once daily for 2 weeks in subjects with cryopyrin-associated periodic syndrome (CAPS)

02

Conditions studied

  • Cryopyrin-associated Periodic Syndromes (CAPS)

Keywords

  • JTE-162
  • Efficacy
  • Safety
  • Tolerability
  • Cryopyrin-associated periodic syndromes
  • CAPS
  • Pharmacokinetics
03

In context

Cryopyrin-Associated Periodic Syndromes

35 studies on the registry are indexed under Cryopyrin-Associated Periodic Syndromes; 5 are open to participants now.

This study's enrollment of 5 is below the median of 19 across 27 interventional studies indexed under Cryopyrin-Associated Periodic Syndromes.

Browse Cryopyrin-Associated Periodic Syndromes studies →

Lead sponsor

Akros Pharma Inc. is the lead sponsor of 25 studies on the registry; none are open to participants now.

Of its 5 completed or terminated interventional studies of FDA-regulated products, 4 (80%) have results posted.

First submitted before Akros Pharma Inc. became part of Shionogi.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosed with familial cold autoinflammatory syndrome (FCAS) or Muckle-Wells syndrome (MWS) confirmed by:
  • Clinical History: At least 2 typical clinical symptoms (e.g., urticarial skin rash, myalgia, arthralgia, recurrent fever, fatigue/malaise, conjunctivitis or other autoinflammatory symptoms) prior to the Screening Visit; AND
  • Genetic Confirmation: Confirmed nucleotide-binding and oligomerization domain (NOD)-like receptor family pyrin domain containing 3 (NLRP3) mutation;
  • Willing to discontinue current anti-interleukin (IL)-1 treatment, if applicable;
  • Demonstrates de novo flaring of CAPS during the Screening Period.

Exclusion criteria

Exclusion Criteria:

  • Has chronic infantile neurologic cutaneous articular syndrome (CINCA)/neonatal-onset multisystem inflammatory disease (NOMID);
  • Has a history or presence of amyloidosis, progressive hearing loss, organ damage or any symptom contraindicating anti-IL-1 treatment ;
  • Has active systemic bacterial, fungal or viral infection(s) within 14 days prior to Day 1 or a history of recurrent infectious diseases
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
5 participants (actual)

Study arms

  • Experimental
    JTE-162 Tablets

    Dose 1 once daily for 2 Weeks

    Drug: JTE-162

Interventions

  • DrugJTE-162

    Tablets containing JTE-162

06

What researchers measure

Primary outcomes

  1. Change and percent change from baseline to end of treatment (EOT) in high-sensitivity C-reactive protein (hs-CRP)

    Time frame: 2 Weeks

  2. Change and percent change from baseline to EOT in Serum amyloid A (SAA)

    Time frame: 2 Weeks

  3. Change and percent change from baseline to EOT in Interleukin (IL)-6

    Time frame: 2 Weeks

  4. Change and percent change from baseline to EOT in Key symptom score (KSS)

    Time frame: 2 Weeks

  5. Change and percent change from baseline to EOT in Individual symptom score on Daily Health Assessment Form, Second Generation (DHAF2)

    Time frame: 2 Weeks

  6. Change and percent change from baseline to EOT in Global assessments of disease activity on DHAF2

    Time frame: 2 Weeks

  7. Change and percent change from baseline to EOT in Global CAPS symptom assessment by the Investigator

    Time frame: 2 Weeks

  8. Change and percent change from baseline to EOT in Individual CAPS symptom assessment by the Investigator

    Time frame: 2 Weeks

  9. Number of adverse events

    Time frame: 4 Weeks

  10. JTE-162 post-dose plasma concentrations on Day 1

    Time frame: 1 Day

  11. JTE-162 trough plasma concentrations on Days 2, 3 and 4, and at the Week 2 Visit (Day 15±2)

    Time frame: Day 2, Day 3, Day 4 and Day 15±2

07

Study locations

1 site
  • Gordon Sussman Clinical Research Inc.
    North York, Ontario M3B 3S6, Canada
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2026 to primary completion in Sep 2026, 7 months.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 18, 2025
First posted
Nov 25, 2025
StartActual
Feb 2, 2026
Primary completionActual
Sep 9, 2026
CompletionActual
Sep 10, 2026
Last update
Oct 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Sep 10, 2026→Sep 9, 2026
Oct 9, 2026
Show all 1 update
  1. Oct 9, 2026
    Primary completion Sep 10, 2026→Sep 9, 2026
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07247266
Lead sponsor
Akros Pharma Inc.
Collaborators
PPD Development, LP
Responsible party
Sponsor
First posted
Nov 25, 2025
Start date
Feb 2, 2026
Primary completion
Sep 9, 2026
Completion
Sep 10, 2026
Last update
Oct 9, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion